Bone Density and Fracture Prevention

How the mineral strontium supports bone formation, improves density, and reduces fracture risk — and what research says about supplementing with strontium citrate

Strontium is a trace mineral that behaves similarly to calcium in the body — it settles into bone tissue and, at the right amounts, supports both the formation of new bone and the slowing of bone breakdown. While strontium ranelate was prescribed in Europe for osteoporosis for over a decade, strontium citrate is the form commonly available as a dietary supplement. Research suggests it may help improve bone mineral density when taken as part of a broader bone-health protocol, particularly for people at risk of osteoporosis [1][2].

How Strontium Works in Bone

Strontium sits just below calcium on the periodic table, which means the body handles it through many of the same pathways. Once absorbed, strontium is taken up into bone mineral — it replaces some calcium atoms in the hydroxyapatite crystals that give bone its hardness [3].

Beyond this structural role, strontium appears to work through a receptor on bone cells called the calcium-sensing receptor (CaSR). Activating this receptor triggers two effects at once: it encourages osteoblasts (cells that build new bone) to proliferate, and it suppresses osteoclasts (cells that break bone down). This dual action — building up while slowing breakdown — is what made strontium ranelate attractive as an osteoporosis drug [4].

The 2020 mechanisms review notes, however, that the bone-strengthening effects may come at least partly from physical changes to the bone's structure: strontium expands the crystal lattice slightly and forms additional molecular bonds that help bone absorb impact before fracturing, rather than purely from increased bone formation [3].

Strontium Ranelate vs. Strontium Citrate

Most of the large clinical trials used strontium ranelate, a pharmaceutical formulation not approved in the US. The SOTI trial (2004) — one of the landmark studies — enrolled 1,649 postmenopausal women with osteoporosis and found that strontium ranelate reduced new vertebral fractures by 49% in the first year and 41% over three years. Lumbar spine bone mineral density increased by 14.4% at 36 months [1].

Strontium citrate is the supplement form available in North America. A mouse-model study comparing the three strontium forms (ranelate, citrate, chloride) found that strontium citrate produced the weakest increase in bone tissue mineral density of the three, though all forms still elevated strontium content in bone [5]. Human data on strontium citrate alone is limited.

The most encouraging human evidence for strontium citrate comes from the COMB study, which combined strontium citrate (680 mg/day) with vitamin D3, vitamin K2, magnesium, and DHA. After one year, compliant participants showed 3–8% improvements in bone mineral density at the femoral neck, spine, and hip — results comparable to or exceeding outcomes from pharmaceutical agents in indirect comparisons [2].

Important Caveat: BMD Readings

Because strontium is denser than calcium, it artificially inflates dual-energy X-ray absorptiometry (DXA) scan readings. The 14.4% BMD increase seen in the SOTI trial corrected down to about 8.1% after accounting for strontium's physical density. If you are using DXA scans to track bone health while taking strontium, your doctor should be aware of this effect to avoid overestimating improvement.

Dosage and Pairing

The COMB study used 680 mg of strontium citrate per day. Strontium should be taken a few hours apart from calcium supplements, as the two minerals compete for the same intestinal transporters. Pairing strontium with vitamin D3, vitamin K2, and magnesium — as was done in the COMB protocol — makes physiological sense, since all four support bone mineral metabolism through different mechanisms.

See our vitamin K2 page for how K2 directs minerals into bone rather than soft tissue, and our magnesium page for its role in activating vitamin D and bone enzymatic processes.

Evidence Review

The SOTI Trial (Meunier et al., 2004)

The Spinal Osteoporosis Therapeutic Intervention (SOTI) trial is the foundational study for strontium in osteoporosis. This multinational RCT enrolled 1,649 postmenopausal women (mean age 69) with osteoporosis and at least one previous vertebral fracture. Participants received 2 g/day of strontium ranelate or placebo for three years.

Results: relative risk of new vertebral fracture was 0.59 (95% CI: 0.48–0.73), representing a 41% reduction over the trial period and a 49% reduction in year one alone. BMD at the lumbar spine increased 14.4% and at the femoral neck 8.3% at month 36. No significant differences in serious adverse events were observed between groups at this dosing level [1].

This trial is high-quality evidence — large sample, randomized, placebo-controlled — but applies directly to strontium ranelate in a patient population with established osteoporosis, not to strontium citrate supplementation in the general population.

The COMB Study (Genuis & Bouchard, 2012)

This observational intervention enrolled 172 participants with low bone density and tracked outcomes over one year using a multinutrient protocol that included strontium citrate (680 mg/day), vitamin D3 (2,000 IU), vitamin K2 (100 mcg), magnesium (25 mg), and DHA (1,200 mg). The compliant group (N=77) showed statistically significant BMD improvements across skeletal sites, including a mean 3.8% increase at the femoral neck. The authors noted results comparable to or better than bisphosphonate outcomes in published literature [2].

Key limitation: no randomized control arm, so causality cannot be established. The combination supplement protocol also makes it impossible to isolate strontium citrate's contribution. Nevertheless, the study provides early human evidence that strontium citrate, when combined with synergistic micronutrients, may support clinically meaningful bone density gains.

Mechanisms Review (Marx et al., 2020)

This Bone Reports review synthesized preclinical and clinical data on strontium's mechanism of action. The authors distinguish between two proposed pathways:

Cellular (anabolic/anticatabolic): Strontium activates the calcium-sensing receptor, promoting osteoblast differentiation and suppressing osteoclastogenesis via the RANK/RANKL/OPG pathway. In vitro evidence is robust; clinical evidence for net anabolic effects is weaker.
Physiochemical: Strontium incorporation into hydroxyapatite crystals increases crystal size and alters lattice parameters. The resulting bone material shows different fracture mechanics — forming sacrificial bonds that absorb energy and prevent crack propagation. The authors argue this physiochemical effect may account for a significant portion of strontium's observed antifracture efficacy independent of measured BMD changes [3].

Bone Metabolism Review (Kołodziejska et al., 2021)

This International Journal of Molecular Sciences review covers strontium's role across bone tissue metabolism, confirming the dual osteoblast-stimulating / osteoclast-inhibiting mechanism and highlighting the importance of the CaSR pathway. The review also notes strontium's incorporation into calcium hydroxyapatite as a therapeutic principle in bone biomaterials and dental applications. The authors identify dosing precision as critical — excess strontium at non-physiological concentrations can paradoxically impair bone quality [4].

Formulation Comparison (Tomczyk-Warunek et al., 2024)

This controlled mouse study compared strontium ranelate, strontium citrate, and strontium chloride over 16 weeks in an ovariectomized osteoporosis model. All three forms increased bone tissue mineral density and strontium content, but strontium citrate produced the smallest effect on bone mineral density among the three formulations tested. Strontium chloride produced intermediate results; strontium ranelate showed superior efficacy [5].

This finding is relevant for supplement users: the citrate form available over the counter appears to be the least potent formulation studied in animal models. Whether this difference translates meaningfully to humans at typical supplement doses remains unknown.

Safety Considerations

Strontium ranelate — the pharmaceutical form — was associated with increased venous thromboembolism risk (RR approximately 1.42, annual incidence ~0.7%) in Phase 3 trials, which contributed to its withdrawal from most markets [1]. This risk has not been reported with strontium citrate supplementation in the studies reviewed.

The primary practical concern with strontium citrate is its ability to artificially elevate DXA readings, which can mislead monitoring. Clinicians following patients on strontium supplementation should account for this artifact when interpreting bone density trends.

Overall, the evidence base for strontium in osteoporosis is strongest for pharmaceutical-grade strontium ranelate in high-fracture-risk populations. The evidence for strontium citrate as a supplement is preliminary but promising, particularly when used as part of a comprehensive bone-health micronutrient protocol.

References

The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosisMeunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY. New England Journal of Medicine, 2004. PubMed 14749454 →
Combination of Micronutrients for Bone (COMB) Study: Bone Density after Micronutrient InterventionGenuis SJ, Bouchard TP. Journal of Environmental and Public Health, 2012. PubMed 22291722 →
A review of the latest insights into the mechanism of action of strontium in boneMarx D, Rahimnejad Yazdi A, Papini M, Towler M. Bone Reports, 2020. PubMed 32395571 →
The Influence of Strontium on Bone Tissue Metabolism and Its Application in Osteoporosis TreatmentKołodziejska B, Stępień N, Kolmas J. International Journal of Molecular Sciences, 2021. PubMed 34207344 →
Influence of Various Strontium Formulations (Ranelate, Citrate, and Chloride) on Bone Mineral Density, Morphology, and Microarchitecture: A Comparative Study in an Ovariectomized Female Mouse Model of OsteoporosisTomczyk-Warunek A, Turżańska K, Tomczyk A, Jabłoński M, Radzki RP, Bieńko M. International Journal of Molecular Sciences, 2024. PubMed 38612883 →